Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

NEUROLOGICAL RESEARCH, published by TAYLOR & FRANCIS LTD, is a distinguished journal focusing on the diverse and evolving field of neurology. Established in 1979, this journal has been a prominent platform for disseminating groundbreaking research and clinical advances up to 2024. With an ISSN of 0161-6412 and an E-ISSN of 1743-1328, it offers valuable insights for researchers, professionals, and students interested in the intricate workings of the nervous system. The journal holds a respectable Q2 ranking in the field of Medicine (miscellaneous) and Q3 in the categories of Neurology and Clinical Neurology, reflecting its commitment to high-quality research. Although NEUROLOGICAL RESEARCH does not currently offer an open access option, its contributions to the literature are vital for fostering advancements in neurological understanding and treatment. With an engaged readership and a mission to advance scientific knowledge, NEUROLOGICAL RESEARCH serves as a crucial resource for anyone dedicated to neurological health and innovation.

EPILEPSY & BEHAVIOR is a premier journal dedicated to advancing the field of neurology and behavioral neuroscience, published by Academic Press Inc. Elsevier Science. With a focus on the complex interplay between epilepsy and behavioral disorders, this journal serves as a pivotal platform for researchers, clinicians, and educators alike. The journal holds a commendable position with a Q2 ranking in key categories such as Behavioral Neuroscience and Clinical Neurology, highlighting its influence and contributions to the scientific community. Notably, EPILEPSY & BEHAVIOR is indexed in Scopus, ranking in the top percentiles across various related fields, which underscores the quality and relevance of the research it publishes. As it navigates from its inception in 2000 to its ongoing work into 2024, the journal remains committed to disseminating high-quality research and insights that address critical issues in epilepsy and associated behavioral challenges, providing invaluable resources for ongoing education and innovation in the field.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Clinical Epileptology, published by Springer Heidelberg, is an emerging open-access journal that aims to advance the understanding of epilepsy through rigorous research and clinical studies. With an ISSN of 2948-104X and E-ISSN of 2948-1058, this journal serves as a vital platform for researchers, clinicians, and students within the fields of Neurology, Pediatrics, and Perinatology. Although still in its formative years, spanning from 2023 to 2024, the journal aspires to fill the knowledge gaps in epilepsy research, thereby improving patient outcomes. Despite its initial Scopus rankings placing it within the 12th and 19th percentiles in respective categories, Clinical Epileptology is poised to make a significant impact by fostering interdisciplinary collaboration and disseminating high-quality findings. With options for open access, this journal ensures that groundbreaking research is readily available to a global audience, encouraging the ongoing dialogue that is crucial to advancing the field. Intended for a diverse readership, including academic researchers, healthcare professionals, and students, Clinical Epileptology is committed to becoming a cornerstone of epilepsy research.

Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.

HEADACHE is a premier academic journal dedicated to advancing the study of headache disorders through innovative research and clinical insights. Published by WILEY, this influential journal has been serving the neurology community since its inception in 1961 and is recognized as a leader in its field, boasting an impressive Q1 ranking in both Neurology and Neurology (clinical) categories for 2023. With a robust Scopus ranking of #48 in clinical neurology and #26 in neuroscience, HEADACHE consistently publishes high-quality research that contributes to the understanding and treatment of headache disorders worldwide. Although it does not offer open access options, the journal remains accessible to a wide audience through various institutional subscriptions. It aims to provide a platform for researchers, healthcare professionals, and students to exchange ideas and develop new strategies for headache management, making it an essential resource for those dedicated to improving patient outcomes in this challenging area of healthcare.

REVISTA DE NEUROLOGIA is a distinguished academic journal focusing on the broad fields of neurology and medicine, published in Spain since its inception in 1959. The journal plays a vital role in disseminating significant research findings, clinical studies, and advancements in neurological science, catering to an audience of researchers, clinicians, and students alike. With an ISSN of 0210-0010 and an E-ISSN of 1576-6578, this quarterly publication has maintained its commitment to enhancing the understanding of neurological disorders and therapies through rigorous peer-reviewed articles. While currently not classified as open access, it is indexed in Scopus, holding a rank of #253 out of 400 in the category of Medicine (Neurology), reflecting its relevance in the field with a 36th percentile. The journal is positioned within the Q3 quartile for both Medicine (miscellaneous) and Clinical Neurology categories as of 2023. Based in Barcelona, Spain, it is a vital resource for anyone devoted to the advancement of knowledge and practice in neurology.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.